Review

Novel Nuclear Medicine Imaging Applications in Immuno-Oncology

Stefano Frega 1,*, Alessandro Dal Maso 2✉, Giulia Pasello 1, Lea Cuppari 3✉, Laura Bonanno 1✉, PierFranco Conte 1,2✉ and Laura Evangelista 4✉

1 Oncology 2 Unit, Department of Medical Oncology, Veneto Institute of Oncology IOV – IRCCS, 35128 Padova, Italy; giulia.pasello@iov.veneto.it (G.P.); laura.bonanno@iov.veneto.it (L.B.); pierfranco.conte@unipd.it (P.C.)
2 Department of Surgery, Oncology and Gastroenterology, University of Padua, 35128 Padova, Italy; alessandro.dalmaso@iov.veneto.it
3 Nuclear Medicine Unit, Veneto Institute of Oncology IOV–IRCCS, University of Padua, 35128 Padova, Italy; lea.cuppari@gmail.com
4 Nuclear Medicine Unit, Department of Medicine, University of Padua, 35128 Padova, Italy; laura.evangelista@aopd.veneto.it
* Correspondence: stefano.frega@iov.veneto.it; Tel.: +39-049-8215931

Received: 19 April 2020; Accepted: 19 May 2020; Published: 21 May 2020

Abstract: The global immuno-oncology pipeline has grown progressively in recent years, leading cancer immunotherapy to become one of the main issues of the healthcare industry. Despite their success in the treatment of several malignancies, immune checkpoint inhibitors (ICIs) perform poorly in others. Again, ICIs action depends on such a multitude of clinico-pathological features, that the attempt to predict responders/long-responders with ad-hoc built immunograms revealed to be quite complex. In this landscape, the role of nuclear medicine might be crucial, with first interesting evidences coming from small case series and pre-clinical studies. Positron-emission tomography (PET) techniques provide functional information having a predictive and/or prognostic value in patients treated with ICIs or adoptive T-cell therapy. Recently, a characterization of the tumor immune microenvironment (TiME) pattern itself has been shown to be feasible through the use of different radioactive tracers or image algorithms, thus adding knowledge about tumor heterogeneity. Finally, nuclear medicine exams permit an early detection of immune-related adverse events (irAEs), with on-going clinical trials investigating their correlation with patients’ outcome. This review depicts the recent advances in molecular imaging both in terms of non-invasive diagnosis of TiME properties and benefit prediction from immunotherapeutic agents.

Keywords: nuclear medicine; positron-emission tomography; single-photon emission computed tomography; immunotherapy; immune checkpoint inhibitors

1. Immuno-Oncology (I-O)

The host immune system interacts with tumor cells through the activation of innate and adaptive immune mechanisms. Initially, transformed cells are eliminated by a competent immune system. Nevertheless, sporadic tumor cells manage to survive immune destruction and may enter an equilibrium phase during which editing occurs. Finally, immunologically sculpted tumors begin to grow progressively, establish an immunosuppressive tumor microenvironment and become clinically apparent [1]. The immune system–tumor interaction is targeted by immunotherapy, with the aim of stimulating the immune system to direct immune-mediated responses against the tumor.

The global I-O pipeline has grown progressively in last years. The administration of interleukin-2 (IL-2) and the adoptive transfer of antitumor T cells grown in IL-2 represented the first effective
immunotherapies for cancer in humans [2]. Toll-like receptor agonist imiquimod has been used to treat a variety of skin cancers including basal cell cancer, squamous cell cancer, lentigo maligna melanoma, and cutaneous T-cell lymphoma [3]. Recombinant interferon α-2b is indicated in hairy cell leukemia, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, and as adjuvant therapy in malignant melanoma [4]. Calmette-Guerin bacillus is the gold standard adjuvant treatment of high-risk non-muscle invasive bladder cancer [5].

Moreover, the development of immune checkpoint inhibitors (ICIs) is a revolutionary milestone in the field of I-O. ICIs reinvigorate antitumor immune responses by interrupting co-inhibitory signaling pathways and promote immune-mediated elimination of tumor cells. Anti-programmed-death 1 (PD-1) nivolumab and pembrolizumab, anti-programmed death-ligand 1 (PD-L1) atezolizumab, durvalumab and avelumab, and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) ipilimumab are the standard of care in adjuvant treatment or advanced disease treatment for many solid tumors (Table 1).

Table 1. Immune checkpoint inhibitor for solid tumors (European Medicines Agency and Food and Drugs Administration approval).

| Immune Checkpoint Inhibitor | Solid Tumor | Reference |
|-----------------------------|-------------|-----------|
| **Adjuvant Setting**        |             |           |
| Ipilimumab                  | Malignant melanoma | [6]       |
| Nivolumab                   | Malignant melanoma | [7]       |
| Pembrolizumab               | Malignant melanoma | [8]       |
| **Advanced Disease Setting**|             |           |
| Ipilimumab                  | Malignant melanoma | [9]       |
| Nivolumab                   | Malignant melanoma | [10]      |
|                            | Non-small cell lung cancer | [11,12] |
|                            | Renal cell carcinoma | [13]     |
|                            | Hodgkin’s lymphoma | [14]     |
|                            | Head and neck cancer | [15]     |
|                            | Urothelial carcinoma | [16]    |
|                            | Mismatch-repair deficient/Microsatellite instability-high colorectal carcinoma | [17] |
|                            | Hepatocellular carcinoma | [18] |
| Nivolumab plus Ipilimumab   | Malignant melanoma | [19]       |
|                            | Renal cell carcinoma | [20]       |
|                            | Mismatch-repair deficient/Microsatellite instability-high colorectal carcinoma | [21] |
| Pembrolizumab               | Malignant melanoma | [22]       |
|                            | Non-small cell lung cancer (with or without chemotherapy) | [23–25] |
|                            | Renal cell carcinoma (with axitinib) | [26] |
|                            | Hodgkin’s lymphoma | [27]     |
|                            | Head and neck cancer | [28]     |
|                            | Urothelial carcinoma | [29,30] |
|                            | Hepatocellular carcinoma | [31] |
|                            | Gastric cancer | [32]     |
|                            | Esophageal cancer | [33]     |
|                            | Cervical cancer | [34]     |
|                            | Merkel cell carcinoma | [35] |
|                            | Small cell lung cancer | [36] |
| Atezolizumab                | Urothelial carcinoma | [37,38] |
|                            | Non-small cell lung cancer (with or without chemotherapy and bevacizumab) | [39–41] |
|                            | Small cell lung cancer (with carboplatin and etoposide) | [42] |
|                            | Triple-negative breast cancer (with nab-paclitaxel) | [43] |
However, despite these substantial advances, only a subset of patients receiving ICIs derive clinical benefit. It is then crucial to identify and to develop predictive biomarkers of ICIs response. PD-L1 expression and tumor mutation burden are the only predictive factors validated in phase III clinical trials, but are still imperfect since there are ICI non-responders expressing high biomarkers levels and ICI responders with low biomarkers levels. New determinants of response are being investigated, with strategies encompassing multiple biomarkers [49,50].

2. Cancer, Nuclear Medicine (NM) and Response to I-O

2.1. Nuclear Medicine

Nuclear medicine is a branch of medicine using radionuclides in the diagnosis and treatment of diseases. Diagnostic applications consist in “functional imaging” and are based on the ability of radiopharmaceutical agents to concentrate in pathological tissues and to emit radiations that are revealed by external detectors and then recorded. Therapeutic approaches exploit selective concentration of radiopharmaceutical agents in pathological tissues and the use of the radiations to destroy them. Techniques of nuclear medicine imaging include two-dimensional scintigraphy, three-dimensional single-photon emission computed tomography (SPECT) and positron emission tomography (PET), and hybrid techniques combining computed tomography (CT) or magnetic resonance imaging (MRI) scans with SPECT or PET [51].

$^{2-\text{[18}F\text{]fluoro-2-deoxy-\text{d-glucose}}}$ ($^{18}\text{F-FDG or FDG})$ PET/CT has become an established standard nuclear imaging modality in oncology [52] based on the finding that tumor hypoxic cells have increased glucose demand and, consequently, FDG uptake and accumulation [53]. FDG-PET/CT is thus widely used in cancer diagnosis, staging, and response to treatment evaluation [54–56].

However, some drawbacks have to be mentioned [57]. Infection and inflammation can lead to false positive findings. Another limitation is that some organs display a higher physiological FDG uptake (i.e., brain, myocardial tissue, brown fat) and therefore are not studied with this modality. Moreover, FDG-PET/CT can result false negative for lesions or $<8–10$ mm and for several histotypes. Hyperglycemia has to be correctly managed to convey a valid exam. Furthermore, FDG-PET/CT is nonspecific for tumor subtypes. Finally, risk–benefit considerations should minimize radiation exposure. For all these reasons, clinical information exchange between oncologists and nuclear medicine specialists is crucial for patients’ care and outcomes [54–56].

2.2. Assessment of Tumor Response

Assessment of response represents a measure of antitumor drug activity. Radiological overall response rate is the primary endpoint of about 70% of phase II trials. Thus, positive trials are the basis of accelerated approval in refractory advanced disease, a setting where there is no available therapy [58]. Furthermore, response assessment is a cornerstone of daily clinical practice.

Practically, response assessment starts with summing the size of tumor lesions in a baseline CT scan before beginning a new therapy. After a specified time, the relative change of the sum of lesion sizes is registered. Finally, a threshold on this relative change is applied to decide whether treatment should be administered or discontinued. Historically, the WHO Response Criteria were first published...
in 1981 and were based on bidimensional measurements [59]. As CT scans were more easily available, the WHO Criteria were simplified and harmonized by the Response Evaluation Criteria in Solid Tumors (RECIST) in which unidimensional measurements were considered [60]. A further update was provided by the RECIST 1.1 version, including revised specifications on measurable disease, nodal disease, and progressive disease [61].

Nevertheless, less than half of the studies that met their response endpoint measured with RECIST criteria in a phase II clinical trial are successful in phase III clinical trials [62–64]. It has been proposed that response assessment with FDG-PET could be more sensitive and specific for the detection of metastatic disease. In particular, bone disease is not evaluable by RECIST criteria. Moreover, stable disease as defined by RECIST criteria could represent on the one hand a consequence of tumor growth inhibition by effective therapy, on the other hand a result of an indolent tumor biology, whereas it is more likely that growth inhibition results in a decrease of tumor FDG uptake [65].

Two metabolic response criteria were thus developed. European Organization for Research and Treatment of Cancer (EORTC) PET response criteria were based on standalone PET imaging and focused on evaluation of only one lesion [66]. PET Response Criteria in Solid Tumors (PERCIST) were applied to PET/CT scans and deal with multiple lesions evaluation [67,68]. Moreover, main differences include the use of standardized uptake value (SUV) mean in EORTC criteria compared to the SUV peak normalized by lean body mass (SULpeak) used in PERCIST criteria as the quantitative parameter, finally a different threshold for progressive metabolic disease is used. Robust clinical validation is still awaited.

2.3. Assessment of Tumor Response to Immunotherapy

Response assessment for I-O must deal with a unique challenge, pseudoprogression, that is a temporary increase in tumor size, meeting the criteria for progressive disease based on RECIST, which is lately not confirmed. Pseudoprogression is caused by immune cells infiltrating tumor lesions. Its prevalence is up to 10%, and it has been characterized in malignant melanoma studies [69,70].

Four new response criteria have been proposed to solve this issue and all of these require a confirmation of progressive disease [71]. Immune-related response criteria (irRC) are based on WHO criteria, and therefore on bidimensional measurements [72]. Immune-related response evaluation criteria in solid tumors (irRECIST) combine irRC with RECIST 1.1 criteria, thus rely on unidimensional measurements [73]. Immune response evaluation criteria in solid tumors (iRECIST) are based on RECIST 1.1, too, but differ from irRECIST because they do not include measurements of the new lesions on tumor burden [74]. Immune-modified response evaluation criteria in solid tumors (imRECIST) are similar to irRECIST [75].

IrRC and irRECIST were clinically validated in patients with advanced malignant melanoma treated with ipilimumab, imRECIST in patients with advanced NSCLC and metastatic urothelial carcinoma treated with atezolizumab, whereas iRECIST are based on a consensus statement. The RECIST working group recommends that recent trials should use RECIST 1.1 to define the primary and secondary efficacy-based endpoints and reserve irRC or irRECIST for exploratory endpoints [74].

The role of already published metabolic criteria was investigated in patients treated with immunotherapy. EORTC criteria applied to PET/CT evaluation after two cycles of ipilimumab on 22 advanced melanoma patients were found to be predictive of final treatment outcome [76]. Retrospective baseline and 1-year PET/CT analysis with EORTC criteria of 104 metastatic melanoma patients treated with nivolumab or nivolumab and ipilimumab showed that patients with complete metabolic responses at 1 year had ongoing responses to therapy thereafter [77]. PERCIST criteria were used to evaluate response on a PET/CT scan 1 month after the start of nivolumab in 24 advanced NSCLC patients, metabolic responses were closely associated with therapeutic response and survival [78].

Likewise, semi quantitative parameters were found to be predictive of outcome in patients treated with immunotherapy. This could be the case for SUV, metabolic tumor volume (MTV), and tumor total lesion glycolysis (TLG). These three variables define the entire metabolic tumor burden (MTB), that may represent a reliable value to predict treatment success, being known that I-O work better in a context
of low tumor load [79]. Variations in MTV and TLG in FDG-PET/CT scans taken before and after 4 cycles of nivolumab in 20 patients with metastatic NSCLC correlated with objective response by CT scan [80]. Baseline SUVmax and SUVmean identified progression after 8 weeks of therapy in 27 NSCLC patients treated with nivolumab or pembrolizumab [81]. Increased SUVmax and SULpeak of the most FDG-avid lesion at interim PET/CT identified non-responders in 30 advanced melanoma patients treated with pembrolizumab [82]. Whole-body maximum SUV (SUVmaxwb) in 32 advanced NSCLC patients treated with nivolumab correlated with response [83]. Moreover, an associated flare response on FDG PET/CT imaging at 1 week post-therapy defined as >100% increase in tumor SUVmax between baseline and post-therapy scans was found to be predictive of a complete response to immunotherapy, and this correlated usually with evidence of T cell reinvigoration in the blood at 1 week post therapy [84].

In parallel, several I-O-adapted metabolic criteria have been proposed. PET/CT Criteria for Early Prediction of Response to Immune Checkpoint Inhibitor Therapy (PECRIT) are based on RECIST 1.1 to define complete response, partial response and progressive disease, whereas percent change in SULpeak by PERCIST criteria is used to distinguish patients with stable disease per RECIST 1.1 and clinical benefit from those with stable disease and no clinical benefit. The comparison of baseline PET/CT scan with a second PET/CT scan at 3–4 weeks after the start of immunotherapy based on PECRIT was able to predict the best overall response at 4 months in 20 patients with advanced melanoma patients treated with nivolumab, ipilimumab or BMS-936559 [85].

Conversely, the number of new FDG-avid lesions was considered in PET Response Evaluation Criteria for Immunotherapy (PERCIMT). Four newly emerged avid lesions on PET/CT scan after 3 months of therapy was found to be predictive of treatment failure in 41 melanoma patients treated with ipilimumab, with the functional size of the new lesions playing an important role in predicting the clinical response [86]. PERCIMT evaluation was applied to PET/CT scan after two cycles of immunotherapy on the same cohort of patients, showing higher sensitivity compared to EORTC criteria in predicting clinical benefit, but specificity in predicting no clinical benefit was not significantly higher [87].

Inflammatory response caused by immunotherapy may confound the ability of FDG-PET to identify patients with a favorable response. Thus, similarly to iRECIST, immune PET Response Criteria in Solid Tumors (iPERCIST) included the concept of disease progression confirmation in PERCIST. iPERCIST were retrospectively applied to a cohort of 28 NSCLC patients treated with nivolumab. All patients underwent a baseline PET/CT scan and a second scan after 2 months of treatment, which was evaluated with the proposed criteria. A metabolic unconfirmed progressive disease was re-evaluated with a third PET/CT scan after 4 weeks. The 1-year survival rates were significantly higher in iPERCIST responders compared with non-responders [88]. Beyond the above seen parameters, even spleen to liver ratio (SLR) has been found to correlate with ICIs efficacy, and thus may represent a novel PET biomarker to evaluate patients’ baseline immune state prior to immunotherapy [89]. All these criteria require further validation.

Figure 1 depicts an overview of CT-based and PET-based response criteria for solid tumors.
(PET)-based (lower panel) response criteria for solid tumors. On the left side are grouped response criteria designed for chemotherapy, on the right side those specifically designed for immunotherapy. RECIST: Response Evaluation Criteria in Solid Tumors, irRC: Immune Related Response Criteria, irRECIST: Immune-related Response Evaluation Criteria in Solid Tumors, imRECIST: Immune-modified response evaluation criteria in solid tumors, iRECIST: Immune response evaluation criteria in solid tumors. EORTC: European Organization for Research and Treatment of Cancer criteria, PERCIST: PET Response Criteria in Solid Tumors, PERCIMT: PET Response Evaluation Criteria for Immunotherapy, PECRIT: PET/CT Criteria for Early Prediction of Response to Immune Checkpoint Inhibitor Therapy, iPERCIST: immune PET Response Criteria in Solid Tumors.

3. NM and Tumor Immune-Microenvironment (TiME) Analysis

The survival benefit from using ICIs varies considerably from patient to patient. ICIs manage to slow down cancer progression, changing completely long-term survival perspective for a subgroup of patients, that goes from 10% to 30%, depending from the tumor types and drug used [90,91]. The reverse of the medal, of course, is that ICIs own poor or no efficacy in a considerable proportion of treated subjects.

Last year, scientific community efforts in oncology were greatly conveyed to unhinge the reasons of this imbalance, trying to recognize the ideal candidate for immunotherapy; the final aim is to sharpen and potentiate ICIs tools [92]. ICIs activity is influenced by several clinical features, tumor histology, and also tumor genes’ expression [93].

The first studied marker has been PD-L1, a protein variously expressed by tumor cells, that for some cancer types correlate well with benefits from specific anti-PD-L1 agents [94]; in fact, some of these drugs have received approval on the basis of tumor PD-L1 expression [95]. For this reason, PD-L1 is to date the most used determinant in patients treated with ICIs worldwide, though it remains an imperfect predictive biomarker.

Evaluating US Food and Drug Administration (FDA) approvals of 45 ICIs agents across 15 tumor types, PD-L1 was found to be predictive in less than a third of them [94]. This phenomenon can be explained by multiple factors. First, PD-L1 expression in individual patients could be heterogeneous possibly being different in different tumor sites but also in a single tumor site, and influenced by the sample itself [96]. Secondarily, ICIs action can be affected by the huge amount of other tumor immune-microenvironment (TiME) properties [97]. B7-H3, a member of the B7 superfamily, is expressed on tumor cells and potentially circumvents CD8+ T-cell-mediated immune surveillance. Anti-B7-H3 immunotherapy combination with anti-PD-1/PD-L1 antibody therapy is a promising approach for B7-H3-expressing cancers [98]. Tumor-infiltrating T-cells (TILs) co-receptors (PD-1, CTLA-4, Lymphocyte-activation gene 3 (LAG-3), etc.) have great importance in the context of TiME, by interacting with tumor cells, becoming new target for a series of new ICIs, some of which already approved. Finally, factors related to the host immune system such as blood biomarkers (peripheral blood mononuclear cells (PBMCs), etc.) could affect ICIs activity [99].

Thus, it would be of extreme importance to consider TiME globally in patients eligible for ICIs. Analyses of TiME on tissue could be affected both by tumor tissue sample itself in terms of quantity and/or quality and by tumor heterogeneity [100]. NM imaging can bypass these two tissue intrinsic limits. Through specific radiotracer-labeled antibody, NM proved to characterize a series of TiME properties, and with good concordance with tissue data. Indeed, surface markers of PBMCs, TILs and tumor cells could be selectively targeted, leading to a successful definition of TiME composition with preclinical animal models, but also in human adults with cancer (Table 2). This constitutes a unique opportunity to overcome the intrinsic limits of TiME analyses on tissue, that results to be moreover both cost and time consuming.
Table 2. Tumor immune-microenvironment analysis with nuclear medicine imaging.

| TiME Type | Target | Radionuclide | Cancer Type         | Setting                      | Comment                                                                 | Reference |
|-----------|--------|--------------|---------------------|------------------------------|-------------------------------------------------------------------------|-----------|
| PBMCs     | CD8    | 89Zr-anti-CD8 | Melanoma cell lines | Preclinical syngeneic tumor  | Detecting change in systemic CD8+ T-cells                               | [101,102] |
| TILs      | IL-2 receptor | 123I-IL-2 | SCCHN               | Human                        | –                                                                       | [103]     |
|           |        |              | RCC                 | Human                        | Identify patients that less likely will benefit from cytokine treatments | [104]     |
|           | 99mTc-IL-2 | Melanoma     | Human               |                              | Prognostic information                                                 | [105]     |
|           | Melanoma | Human        |                     |                              | –                                                                       | [106]     |
| CD3       | 89Zr    | Bladder cancer lines | Bearing mice | In-vitro and in-vivo (bearing mice) | DFO-anti-CD3 had diminished CD4+ T-cell counts and polarization of the CD8+ T-cell pool towards a memory phenotype | [107]     |
| CTLA-4    | 64Cu-DOTA-anti-CTLA-4 | Colon cancer cell lines | Bearing mice | – | – | [108] |
|           | 64Cu-DOTA-ipilimumab | Lung cancer cell lines | In-vitro and in-vivo (bearing mice) | – | – | [109] |
| PD-1      | 89Zr-Df-nivolumab | Lung cancer cell lines | In-vitro and in-vivo (bearing mice) | – | – | [110] |
|           | 64Cu-labeled PET | Melanoma cell lines | Bearing mice | – | – | [111] |
|           | 64Cu-pembrolizumab | Melanoma cell lines | Bearing mice | – | – | [112] |
|           | 89Zr-pembrolizumab | Melanoma cell lines | Bearing mice | – | – | [113] |
| LAG-3     | 89Zr-REGN3767 | Lymphoma cell lines | Bearing mice | – | – | [114] |
| Tumor cells | PD-L1 | 89Zr-DFO-PD-L1 mAb | Breast, gastric, lung cancer cell lines | In-vitro and in-vivo (bearing mice) | Uptake increased with escalating dose of avelumab | [115] |
|           | 68Ga-DOTA-Nb109 | Melanoma cell lines | Bearing mice | – | – | [116] |
| B7-H3     | 89Zr-DS-5573a | Breast, colon cancer cell lines | Bearing mice | – | – | [117] |
| CD-38     | 89Zr-daratumumab | Myeloma cell lines | Bearing mice | – | – | [118] |

The above table depicts the advancements of NM in the determination of different TiME features. For each TiME target, it is specified the radionuclide or the antibody-drug conjugates used, the clinical or preclinical setting, the type of cell line. Finally, any other main information in terms of recognition of target, determination of treatment response is reported as comment. CD: cluster of differentiation; CTLA-4: cytotoxic T-lymphocyte antigen 4; Df: p-SCN-deferoxamine; DFO: desferrioxamine B; DOTA: tetra-azacyclododecanetetra-acetic acid; FoxP3: forkhead box P3; ICI: immune checkpoint inhibitors; IL-2: interleukin-2; LAG-3: lymphocyte-activation gene 3; PBMCs: peripheral blood mononuclear cells; PD-1: programmed cell death protein 1; PD-L1: programmed cell death protein-ligand 1; RCC: renal cell carcinoma; SCCHN: squamous cell carcinoma of the head and neck; TILs: tumor-infiltrating lymphocytes; Treg: Regulatory T cell; 64Cu: copper-64; 68Ga: gallium-68; 123I: iodine-123; 99mTc: technetium-99m; 89Zr: zirconium-89.
Recently, imaging of TiME by PET has gained an excellent progress by the introduction of different tracers targeting fibroblast activation protein (FAP), among which $^{68}$Gallium-labeled chelator-linked FAP inhibitors (FAPIs) and $^{18}$F-labeled glycosylated FAPIs [119]. FAP is highly expressed by cancer-associated fibroblasts (CAFs), that are generally associated with poor prognosis and represent for some cancer types one of the main reason of resistance to immunotherapy [120].

NM imaging can provide a static baseline representation of the identified marker, so having a predictive value, possibly bringing our therapeutic choices to be as careful as possible. Otherwise, these techniques can be used in a more dynamic way, by repeating NM imaging in different disease time-points in patients treated with ICIs. The aim will be to monitor treatment response, by using labeled-radiotracers conjugated with immunotherapeutic agents, with first brilliant results in this sense.

### 3.1. PBMCs-Targeted Imaging

The generation of anti-CD8 $^{89}$Zr-desferrioxamine-labeled cys-diabody permitted a noninvasive immuno-PET tracking of endogenous CD8$^+$ T cells in melanoma immunotherapy models, including anti-PD-L1 agents, antigen-specific adoptive T-cell transfer and agonistic antibody therapy. The great power of such imaging consists in its ability to acquire dynamic information regarding therapy-induced alterations of both PBMCs and TILs component [101].

### 3.2. TILs-Targeted Imaging

Similarly, with an immuno-PET with Zirconium-89($^{89}$Zr)-labeled PEGylated single-domain antibody fragments specific for CD8, Rashidian et al. demonstrated the ability to longitudinally detect TILs in melanoma models and to distinguish responding tumors from those that do not respond to anti-CTLA4 therapy [102].

$^{123}$I-interleukin-2 (IL-2) single-photon emission computed tomography (SPECT) well depicted TILs in cancer patients, also giving a preliminary response to cytokine treatment [103,104], while TILs targeting through $^{99m}$Tc-IL-2 in melanoma patients treated with I-O permits to acquire information about pseudo-progression and prognosis [105,106]. Prognosis impact has also found to be appraisable by quantifying TILs in animal models of bladder cancer trough anti-CD3 monoclonal antibody (mAb) modified with desferrioxamine (DFO) and radiolabeled with $^{89}$Zr [107]. Recognition of CTLA-4 TILs receptor has been realized by a specific $^{64}$Cu-DOTA-anti-CTLA-4 mAb [108,109], while anti-PD-1 agents labeled with $^{64}$Cu or $^{89}$Zr can detect very precisely PD-1-expressing TILs [110–113]. Moreover, the fully human anti-LAG3 antibody REGN3767, radiolabeled with $^{89}$Zr using the bifunctional chelator p-SCN-Bn-Deferoxamine (DFO) led to an immune-PET detection of LAG-3 expressing TILs [114]. NM individuation of PD-1, CTLA-4 and LAG-3 expressed by TILs could assist in patient stratification, disease diagnostics, and monitoring response to ICIs.

### 3.3. Tumor Cell-Targeted Imaging

A similar usefulness may derive from PET-imaging of some proteins expressed directly by tumor cells. High affinity to PD-L1 has been guaranteed by specifically synthetized $^{68}$Ga-labeled single-domain antibody tracer called $^{68}$Ga-NOTA-Nb109, and $^{89}$Zr-DFO-PD-L1 monoclonal antibody [115,116]. Moreover, saturation of B7-H3 tumor cell protein by anti-B7-H3 humanized monoclonal antibody DS-5573a labeled with $^{89}$Zr was demonstrated in tumors responding to DS-5573a therapy [117]. $^{89}$Zr-DFO-daratumumab provides successful whole-body PET visualization of myeloma, and predicts the effectiveness of daratumumab therapy [118].

All these applications represent in a certain way an evolution of the most widely used FDG-PET, already proved as seen to acquire response to ICIs earlier than through the classical CT scan imaging [72,78,79].

### 3.4. Tumor Heterogeneity

The therapeutic approach cannot ignore inter-patients and intra-patient cancer heterogeneity. The latter depends on a complex phenotypic evolution that involve (epi)genetic transformations,
surface markers selections and cell-cycle modifications in response to environmental stimuli [121]. What is more, not only tumor cells but also TiME features might become different [122]. This is quite challenging because prognosis and response to treatments could be thus tightly influenced.

NM may be helpful to visualize tumor heterogeneity, with interesting applications in the field of I-O. Quantitative analyses of canonical $^{18}$F-FDG PET imaging can point out the presence of aggressive tumor foci, which may divert patients’ prognosis [123]; CAFs have found to contribute to the intratumor heterogeneity of $^{18}$F-FDG PET and to enhance tumor uptake [123].

The recognition of TiME and cancer cells markers heterogeneity, through specific tracers, could guide in the future daily therapeutic choices. PD-L1 is the forerunner marker in this sense, with different contributes about its possible discordant expression in different tumor lesions [124–126], but the same concept could be applied to other markers.

4. NM and Immune-Adverse Events (irAEs) Analysis

Immune-related adverse events (irAEs) are unique adverse events caused by activation of an immune response against healthy tissues due to immunotherapy. IrAEs occur in about two thirds of patients treated with IO, of which 14% is grade 3 or superior [127]. Timely detection and correct management of irAEs according to their grading, with suspension of IO or eventually immunosuppressive medication, are crucial [128,129]. If not treated, irAEs could require hospitalization and may lead to life-threatening complications. Therefore, predictive markers for irAEs are an unmet clinical need [130].

 Diagnosis of irAEs is made through clinical, biohumoral, and radiological investigations. Early radiological detection of irAEs could improve their correct management. In a recent study, medical imaging detected 74% of irAE in patients treated with anti-PD1. Among typical irAEs, interstitial lung disease is mainly diagnosed with CT scans, as well as enterocolitis and pancreatitis, whereas thyroiditis with ultrasound and hypophysitis with magnetic resonance imaging [131].

Beyond tumor lesions, FDG uptake can be induced by the inflammatory reaction related to irAEs. Thus, sarcoid-like reaction [132,133] and enterocolitis [134] are easily detected by PET/CT scans. PET/CT could also be useful in detecting thyroiditis, hypophysitis, pancreatitis, gastroduodenitis, and cholangitis [131,135–137]. In another study with 35 patients with malignant melanoma receiving nivolumab and ipilimumab combination, 39% of irAEs were diagnosed subsequent to FDG-PET/TC and 11% remained clinically occult [138].

Furthermore, irAEs could predict response to immunotherapy [139]. A retrospective study enrolled 40 patients with malignant melanoma, malignant lymphoma or renal cell carcinoma; all patients with an increase of SUVmax in the thyroid of more than 1.5 on the first restaging scan compared to baseline scan had a complete response to I-O in 1 year [140]. Overt thyroid irAEs could be predicted by baseline thyroid uptake of FDG in another study that enrolled 200 patients treated with nivolumab. In the same study, thyroid irAEs were related to good prognosis in patients diagnosed with lung cancer [141]. As regards to enterocolitis, increased FDG uptake correlated with clinical symptoms but did not predict clinical outcome to ipilimumab in 100 advanced melanoma patients [142]. In a study with 41 patients with malignant melanoma treated with ipilimumab, 4 out of 31 patients having disease control were diagnosed sarcoid-like reaction in the follow-up PET/TC, while none of the patients with progressive disease [143].

5. Conclusions and Future Applications

NM imaging has historically contributed in a decisive way to expand the knowledge about cancer management and cancer response to treatment, providing several functional data. In the context of modern I-O, this could become quite challenging, because each day millions of cancer patients worldwide are treated with I-O therapies, and lots of crucial aspects remain to be clarified. Last decade scientific reports added progressively important pieces to the definition of the complex immune-cancer
cycle, finding out favorable clinical and pathological patterns of response to I-O drugs, and even creating complex predictive algorithms.

Main open questions include the optimal candidate for I-O therapy, the determination of response and appropriate duration of treatments, the mechanisms that underlie primary and secondary resistance to I-O. The goals are I-O empowerment in terms of efficacy and healthcare resources optimization.

As seen, PET-CT scans has shown to predict responders and non-responders to I-O earlier than the conventional CT scan, through the acquisition of both anatomical and metabolic data. Moreover, several PET-CT scan parameters, acquired at baseline or during treatment, have been found to be predictive of response to I-O. NM applications could well depict several predictive TiME features by using different radiotracers and/or drug-radiotracer conjugates, and also precociously recognize drug-induced irAEs usually correlated with I-O benefit. This would permit ideally to change in the near future the approach of cancer care, by selecting the right I-O drug for the right patient, revealing the immunologic reasons of innate and acquired resistance to I-O, and laying the foundations to get around them.

In the last few years, I-O imaging field has been enriched by radiomics, a set of methods used to extract a large amount of quantitative data from biomedical images—called features—aiming to personalize medicine even more. The typical radiomics workflow is a multi-step process, that starts with the acquisition of measurable features and, through different phases of data processing, concludes with data analysis [144]. Radiomics can acquire and deal with traditional radiology imaging (CT, magnetic resonance), but also with PET imaging, building-up mathematical algorithms in order to study tumor characteristics and clinical outcomes. PD-L1 expression of patients affected by head and neck carcinoma (n = 53) has found to be correlated to textural features derived from FDG-PET organization of tumor pixels [145]. PET/CT-based radiomic signature could have both a prognostic value for NSCLC patients that underwent to surgery [146] and a predictive role to identify those patients most likely to benefit from immunotherapy. A multiparametric radiomics signature, built up combining different radiomics features, have shown in fact to well predict durable clinical benefit from immunotherapy in advanced NSCLC patients (n = 99) [147], with other experiences confirming this potentiality [148]. Moreover, radiomics could improve tumor heterogeneity characterization and prognosis prediction, in order to stratify patients to receive therapeutic regimens [123]. Despite its great premises, some concerns exist about applicability of NM radiomics in daily clinical practice [149], and further studies investigating its potential in I-O field are urgently warranted.

Author Contributions: Conceptualization by S.F.; L.E.; A.D.M.; writing—original draft preparation by S.F.; L.E.; A.D.M.; writing—review by L.E.; G.P.; L.C.; L.B.; P.C.; editing by S.F.; A.D.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research did not receive external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Mittal, D.; Gubin, M.M.; Schreiber, R.D.; Smyth, M.J. New insights into cancer immunoediting and its three component phases—Elimination, equilibrium and escape. Curr. Opin. Immunol. 2014, 27, 16–25. [CrossRef] [PubMed]
2. Rosenberg, S.A. IL-2: The first effective immunotherapy for human cancer. J. Immunol. 2014, 192, 5451–5458. [CrossRef] [PubMed]
3. Huen, A.O.; Rook, A.H. Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma. Curr. Opin. Oncol. 2014, 26, 237–244. [CrossRef]
4. Borden, E.C. Interferons α and β in cancer: Therapeutic opportunities from new insights. Nat. Rev. Drug Discov. 2019, 18, 219–234. [CrossRef] [PubMed]
5. Herr, H.W.; Morales, A. History of bacillus Calmette-Guerin and bladder cancer: An immunotherapy success story. J. Urol. 2008, 179, 53–56. [CrossRef]
6. Eggermont, A.M.M.; Chiarion-sileni, V.; Grob, J.J.; Dummer, R.; Wolchok, J.D.; Schmidt, H.; Hamid, O.; Robert, C.; Ascierto, P.A.; Richards, J.M.; et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. *N. Engl. J. Med.* 2016, 375, 1845-1855. [CrossRef]
7. Weber, J.; Mandala, M.; Del Vecchio, M.; Gogas, H.J.; Arance, A.M.; Cowey, C.L.; Dalle, S.; Schenker, M.; Chiarion-Sileni, V.; Marquez-Rodas, I.; et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. *N. Engl. J. Med.* 2017, 377, 1824–1835. [CrossRef]
8. Eggermont, A.M.M.; Blank, C.U.; Mandala, M.; Long, G.V.; Atkinson, V.; Dalle, S.; Haydon, A.; Lichinitser, M.; Khattak, A.; Carlino, M.S.; et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. *N. Engl. J. Med.* 2018, 378, 1789-1801. [CrossRef]
9. Hodi, F.S.; O'Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N. Engl. J. Med.* 2010, 363, 711–723. [CrossRef]
10. Robert, C.; Long, G.V.; Brady, B.; Dutriaux, C.; Maio, M.; Mortier, L.; Hassel, J.C.; Rutkowski, P.; McNeil, C.; Kalinka-Warzocha, E.; et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N. Engl. J. Med.* 2015, 372, 320–330. [CrossRef]
11. Brahmer, J.; Reckamp, K.L.; Baas, P.; Crinò, L.; Eberhardt, W.E.E.; Poddubskaya, E.; Antonia, S.; Pluzanski, A.; Vokes, E.E.; Holgado, E.; et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N. Engl. J. Med.* 2015, 373, 123–135. [CrossRef] [PubMed]
12. BORGHAEI, H.; PAZ-ARES, L.; HORN, L.; SPIGEL, D.R.; STEINS, M.; READY, N.E.; CHOW, L.Q.; VOkses, E.E.; FELIP, E.; HOLGADO, E.; et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N. Engl. J. Med.* 2015, 373, 1627–1639. [CrossRef] [PubMed]
13. Motzer, R.J.; Escudier, B.; McDermott, D.F.; George, S.; Hammers, H.J.; Srinivas, S.; Tykodi, S.S.; Sosman, J.A.; Procopio, G.; Plimack, E.R.; et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. *N. Engl. J. Med.* 2015, 373, 1803–1813. [CrossRef]
14. YOUNES, A.; SANTORO, A.; SHIPP, M.; ZINZANI, P.L.; TIMMERMAN, J.M.; ANSELL, S.; ARMAND, P.; FANALE, M.; RATANATHARATHORN, V.; KURUVILLA, J.; et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial. *Lancet Oncol.* 2016, 17, 1283–1294. [CrossRef]
15. FERRIS, R.L.; BLUMENSCHINE, G.; FAYETTE, J.; GUIGAY, J.; COLEVAS, A.D.; LICITRA, L.; HARRINGTON, K.; KASPER, S.; VOkses, E.E.; EVEN, C.; et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. *N. Engl. J. Med.* 2016, 375, 1856–1867. [CrossRef] [PubMed]
16. SHARMA, P.; RETZ, M.; SIEFFER-RADTKE, A.; BARON, A.; NECCHI, A.; BEDIKE, J.; PLIMACK, E.R.; VAENA, D.; GRIMM, M.O.; BRACARDAS, S.; et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. *Lancet Oncol.* 2017, 18, 312–322. [CrossRef]
17. OVERMAN, M.J.; McDermott, R.; LEACH, J.L.; LONARDI, S.; LENZ, H.J.; MORSE, M.A.; DESAI, J.; HILL, A.; AXELSON, M.; MOSS, R.A.; et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. *Lancet Oncol.* 2017, 18, 1182–1191. [CrossRef]
18. EL-KHOUEIRY, A.B.; SANGRO, B.; YAU, T.; CROCENZI, T.S.; KUDO, M.; HSU, C.; KIM, T.Y.; CHOW, S.P.; TROJAN, J.; WELLING, T.H.; et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dosage escalation and expansion trial. *Lancet* 2017, 389, 2492–2502. [CrossRef]
19. LARKIN, J.; CHIARION-SILENI, V.; GONZALEZ, R.; GROB, J.J.; COWEY, C.L.; LAO, C.D.; SCHADENDORF, D.; DUMMER, R.; SMYLY, M.; RUTKOWSKI, P.; et al. Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma. *N. Engl. J. Med.* 2015, 373, 23–34. [CrossRef]
20. MOTZER, R.J.; TANNIR, N.M.; MCDERMOTT, D.F.; ARÉN FRONtera, O.; MELICHAR, B.; CHOUERUI, T.K.; PLIMACK, E.R.; BARTHELEMY, P.; PORTA, C.; GEORGE, S.; et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. *N. Engl. J. Med.* 2018, 378, 1277–1290. [CrossRef] [PubMed]
21. OVERMAN, M.J.; LONARDI, S.; WONG, K.Y.M.; LENZ, H.J.; GELSMOMINO, F.; AGLIETTA, M.; MORSE, M.A.; VAN CUTSEM, E.; MCDERMOTT, R.; HILL, A.; et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. *J. Clin. Oncol.* 2018, 36, 773–779. [CrossRef] [PubMed]
22. Robert, C.; Schachter, J.; Long, G.V.; Arance, A.; Grob, J.J.; Mortier, L.; Daud, A.; Carlino, M.S.; McNeil, C.; Lotem, M.; et al. Pembrolizumab versus ipilimumab in advanced melanoma. *N. Engl. J. Med.* 2015, 372, 2521–2532. [CrossRef] [PubMed]

23. Herbst, R.S.; Baas, P.; Kim, D.W.; Felip, E.; Pérez-Gra西亚, J.L.; Han, J.Y.; Molina, J.; Kim, J.H.; Arvis, C.D.; Ahn, M.J.; et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. *Lancet* 2016, 387, 1540–1550. [CrossRef]

24. Reck, M.; Rodriguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csőszi, T.; Fülop, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* 2016, 375, 1823–1833. [CrossRef] [PubMed]

25. Gandhi, L.; Rodríguez-Abreu, D.; Gadgeel, S.; Esteban, E.; Felip, E.; De Angelis, F.; Domine, M.; Clingan, P.; Hochmair, M.J.; Powell, S.E.; et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N. Engl. J. Med.* 2018, 378, 2078–2092. [CrossRef] [PubMed]

26. Rini, B.I.; Plimack, E.R.; Stus, V.; Gafanov, R.; Hawkins, R.; Nosov, D.; Pouliot, F.; Alekseev, B.; Soulières, D.; Melchar, B.; et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N. Engl. J. Med.* 2019, 380, 1116–1127. [CrossRef]

27. Chen, R.; Zinzani, P.L.; Fanale, M.A.; Armand, P.; Johnson, N.A.; Brice, P.; Radford, J.; Ribrag, V.; Molin, D.; Vassilakopoulou, T.P.; et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin Lymphoma. *J. Clin. Oncol.* 2017, 35, 2125–2132. [CrossRef]

28. Cohen, E.W.; Soulières, D.; Le Tourneau, C.; Dinis, J.; Licitra, L.; Ahn, M.J.; Soria, A.; Machiels, J.P.; Mach, N.; Mehrara, B.; et al. Pembrolizumab plus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. *Lancet* 2019, 393, 156–167. [CrossRef]

29. Bellmunt, J.; de Wit, R.; Vaughn, D.J.; Fradet, Y.; Lee, J.-L.; Fong, L.; Vogelzang, N.J.; Climent, M.A.; Petrylak, D.P.; Choueiri, T.K.; et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. *N. Engl. J. Med.* 2017, 376, 1015–1026. [CrossRef]

30. Balar, A.V.; Castellano, D.; O’Donnell, P.H.; Grivas, P.; Vuky, J.; Powles, T.; Plimack, E.R.; Hahn, N.M.; de Wit, R.; Pang, L.; et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study. *Lancet Oncol.* 2017, 18, 1483–1492. [CrossRef]

31. Zhu, A.X.; Finn, R.S.; Edeline, J.; Cattan, S.; Ogasawara, S.; Palmer, D.; Verslype, C.; Zaganel, V.; Fortoux, L.; Vogel, A.; et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. *Lancet Oncol.* 2018, 19, 940–952. [CrossRef]

32. Fuchs, C.S.; Doi, T.; Jang, R.W.; Muro, K.; Satoh, T.; Machado, M.; Sun, W.; Jalal, S.I.; Shah, M.A.; Metges, J.P.; et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial. *JAMA Oncol.* 2018, 4, e180013. [CrossRef] [PubMed]

33. Shah, M.A.; Kojima, T.; Hochhausser, D.; Enzinger, P.; Ramborg, J.; Hollebecque, A.; Lordick, F.; Kim, S.-B.; Tajika, M.; Kim, H.T.; et al. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. *JAMA Oncol.* 2019, 5, 546–550. [CrossRef]

34. Chung, H.C.; Ros, W.; Delord, J.-P.; Perets, R.; Italiano, A.; Shapira-Frommer, R.; Manzuk, L.; Piha-Paul, S.A.; Xu, L.; Zeigenfuss, S.; et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. *J. Clin. Oncol.* 2019, 37, 1470–1478. [CrossRef] [PubMed]

35. Nghiem, P.; Bhata, S.; Lipson, E.J.; Sharfman, W.H.; Kudchadkar, R.R.; Brohl, A.S.; Friedlander, P.A.; Daud, A.; Kluger, H.M.; Reddy, S.A.; et al. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. *J. Clin. Oncol.* 2019, 37, 693–702. [CrossRef] [PubMed]

36. Chung, H.C.; Lopez-Martín, J.A.; Kao, S.C.-H.; Miller, W.H.; Ros, W.; Gao, B.; Marabelle, A.; Gottfried, M.; Zer, A.; Delord, J.-P.; et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. *J. Clin. Oncol.* 2018, 36, 8506. [CrossRef]
37. Rosenberg, J.E.; Hoffman-Censits, J.; Powles, T.; Van Der Heijden, M.S.; Balar, A.V.; Necchi, A.; Dawson, N.; O'Donnell, P.H.; Balmanoukian, A.; Loriot, Y.; et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 2016, 387, 1909–1920. [CrossRef]

38. Powles, T.; Durán, I.; van der Heijden, M.S.; Loriot, Y.; Vogelzang, N.J.; De Giorgi, U.; Oudard, S.; Retz, M.M.; Castellano, D.; Bamias, A.; et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018, 391, 748–757. [CrossRef]

39. Rittmeyer, A.; Barlesi, F.; Waterkamp, D.; von Pawel, J.; Gadgeel, S.M.; Hida, T.; Kowalski, D.M.; Dols, M.C.; et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 2017, 389, 255–265. [CrossRef]

40. Socinski, M.A.; Jotte, R.M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodriguez-Abreu, D.; Moro-Sibilot, D.; Thomas, C.A.; Barlesi, F.; et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 2018, 378, 2288–2301. [CrossRef]

41. Reck, M.; Mok, T.S.K.; Nishio, M.; Jotte, R.M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodriguez-Abreu, D.; Moro-Sibilot, D.; et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir. Med. 2019, 7, 387–401. [CrossRef]

42. Horn, L.; Mansfield, A.S.; Szczesna, A.; Havel, L.; Krzakowski, M.; Hochmair, M.J.; Huemer, F.; Losonczy, G.; Johnson, M.L.; Nishio, M.; et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 2018, 379, 2220–2229. [CrossRef] [PubMed]

43. Schmid, P.; Adams, S.; Rugo, H.S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Dieras, V.; Hegg, R.; Im, S.A.; Shaw Wright, G.; et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 2018, 379, 2108–2121. [CrossRef] [PubMed]

44. Kaufman, H.L.; Russell, J.; Hamid, O.; Bhatia, S.; Terheyden, P.; D’Angelo, S.P.; Shih, K.C.; Lebbé, C.; Linette, G.P.; Milella, M.; et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016, 17, 1374–1385. [CrossRef]

45. Patel, M.R.; Ellerton, J.; Infante, J.R.; Agrawal, M.; Gordon, M.; Aljumaily, R.; Britten, C.D.; Dirix, L.; Lee, K.-W.; Taylor, M.; et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): Pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018, 19, 51–64. [CrossRef]

46. Motzer, R.J.; Penkov, K.; Haanen, J.; Rini, B.; Albigez, L.; Campbell, M.T.; Venugopal, B.; Kollmannsberger, C.; Negrier, S.; Uemura, M.; et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 2019, 380, 1103–1115. [CrossRef]

47. Antonia, S.J.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Kurata, T.; Chiappori, A.; Lee, K.H.; De Wit, M.; et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. 2018, 379, 2342–2350. [CrossRef]

48. Massard, C.; Gordon, M.S.; Sharma, S.; Rafii, S.; Wainberg, Z.A.; Luke, J.; Curiel, T.J.; Colon-Otero, G.; Hamid, O.; Sanborn, R.E.; et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J. Clin. Oncol. 2016, 34, 3119–3125. [CrossRef]

49. Havel, J.J.; Chowell, D.; Chan, T.A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer 2019, 19, 133–150. [CrossRef]

50. Camidge, D.R.; Doebele, R.C.; Kerr, K.M. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat. Rev. Clin. Oncol. 2019, 16, 341–355. [CrossRef]

51. McCreany, V.R. Milestones in nuclear medicine. Eur. J. Nucl. Med. 2000, 27, S49–S79. [CrossRef] [PubMed]

52. Hricak, H.; Choi, B.I.; Scott, A.M.; Sugimura, K.; Muellner, A.; Von Schulthess, G.K.; Reiser, M.F.; Graham, M.M.; Dunnicliff, N.R.; Larson, S.M. Global trends in hybrid imaging. Radiology 2010, 257, 498–506. [CrossRef] [PubMed]
53. Shen, B.; Huang, T.; Sun, Y.; Jin, Z.; Li, X.F. Revisit 18F-fluorodeoxyglucose oncology positron emission tomography: “systems molecular imaging” of glucose metabolism. *Oncotarget* 2017, 8, 43536–43542. [CrossRef] [PubMed]

54. Delbeke, D.; Coleman, R.E.; Guiberteau, M.J.; Brown, M.L.; Royal, H.D.; Siegel, B.A.; Townsend, D.W.; Berland, L.L.; Parker, J.A.; Hubner, K.; et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. *J. Nucl. Med.* 2006, 47, 885–895.

55. Boellaard, R.; O'Doherty, M.J.; Weber, W.A.; Mottaghy, F.M.; Lonsdale, M.N.; Stroobants, S.G.; Oyen, W.J.G.; Kotzerke, J.; Hoekstra, O.S.; Pruim, J.; et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0. *Eur. J. Nucl. Med. Mol. Imaging* 2010, 37, 181–200. [CrossRef]

56. Boellaard, R.; Delgado-Bolton, R.; Oyen, W.J.G.; Giammarile, F.; Tatsch, K.; Eschner, W.; Verzijlbergen, F.J.; Barrington, S.F.; Pike, L.C.; Weber, W.A.; et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: Version 2.0. *Eur. J. Nucl. Med. Mol. Imaging* 2015, 42, 328–354. [CrossRef]

57. Griffith, L.K. Use of PET/Ct Scanning in Cancer Patients: Technical and Practical Considerations. *Baylor Univ. Med. Cent. Proc.* 2005, 18, 321–330. [CrossRef]

58. Blumenthal, G.M.; Pazdur, R. Response rate as an approval end point in oncology: Back to the future. *JAMA Oncol.* 2016, 2, 780–781. [CrossRef]

59. Miller, A.B.; Hoogstraten, B.; Staquet, M.; Winkler, A. Reporting results of cancer treatment. *Cancer* 1981, 47, 207–214. [CrossRef]

60. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A.T.; Christian, M.C.; et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J. Natl. Cancer Inst.* 2000, 92, 205–216. [CrossRef]

61. Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur. J. Cancer* 2009, 45, 228–247. [CrossRef] [PubMed]

62. Monzon, J.G.; Hay, A.E.; McDonald, G.T.; Pater, J.L.; Meyer, R.M.; Chen, E.; Chen, B.E.; Dancey, J.E. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome. *Eur. J. Cancer* 2015, 51, 2501–2507. [CrossRef] [PubMed]

63. Vickers, A.J.; Ballen, V.; Scher, H.I. Setting the bar in phase II trials: The use of historical data for determining “go/no go” decision for definitive phase III testing. *Clin. Cancer Res.* 2007, 13, 972–976. [CrossRef] [PubMed]

64. Gan, H.K.; You, B.; Pond, G.R.; Chen, E.X. Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. *J. Natl. Cancer Inst.* 2012, 104, 590–598. [CrossRef] [PubMed]

65. Pinker, K.; Riedl, C.; Weber, W.A. Evaluating tumor response with FDG PET: Updates on PERCIST, comparison with EORTC criteria and clues to future developments. *Eur. J. Nucl. Med. Mol. Imaging* 2017, 44, 55–66. [CrossRef] [PubMed]

66. Young, H.; Baum, R.; Cremerius, U.; Herholz, K.; Hoekstra, O.; Lammertsma, A.A.; Pruim, J.; Price, P. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. *Eur. J. Cancer* 1999, 35, 1773–1782. [CrossRef]

67. Wahl, R.L.; Jacene, H.; Kasamon, Y.; Lodge, M.A. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. *J. Nucl. Med.* 2009, 50, 1225–1505. [CrossRef]

68. O, J.H.; Lodge, M.A.; Wahl, R.L. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. *Radiology* 2016, 280, 576–584. [CrossRef]

69. Di Giacomo, A.M.; Danielli, R.; Guidoboni, M.; Calabrò, L.; Carlucci, D.; Miracco, C.; Volterrani, L.; Mazzei, M.A.; Biagioli, M.; Altomonte, M.; et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: Clinical and immunological evidence from three patient cases. *Cancer Immunol. Immunother.* 2009, 58, 1297–1306. [CrossRef]

70. Chiori, V.L.; Burotto, M. Pseudoprogression and immune-related response in solid tumors. *J. Clin. Oncol.* 2015, 33, 3541–3543. [CrossRef]

71. Kataoka, Y.; Hirano, K. Which criteria should we use to evaluate the efficacy of immune-checkpoint inhibitors? *Ann. Transl. Med.* 2018, 6, 222. [CrossRef] [PubMed]
72. Wolchok, J.D.; Hoos, A.; O’Day, S.; Weber, J.S.; Hamid, O.; Lebbé, C.; Maio, M.; Binder, M.; Bohnsack, O.; Nichol, G.; et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res. 2009, 15, 7412–7420. [CrossRef] [PubMed]

73. Nishino, M.; Giobbie-Hurder, A.; Gargano, M.; Suda, M.; Ramaiya, N.H.; Hodi, F.S. Developing a common language for tumor response to immunotherapy: Immune-related response criteria using unidimensional measurements. Clin. Cancer Res. 2013, 19, 3936–3943. [CrossRef] [PubMed]

74. Seymour, L.; Bogaerts, J.; Perrone, A.; Ford, R.; Schwartz, L.H.; Mandrekar, S.; Lin, N.U.; Litière, S.; Dancey, J.; Chen, A.; et al. iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017, 18, e143–e152. [CrossRef]

75. Hodi, F.S.; Ballinger, M.; Lyons, B.; Soria, J.C.; Nishino, M.; Tabernero, J.; Powles, T.; Smith, D.; Hoos, A.; McKenna, C.; et al. Immune-modified response evaluation criteria in solid tumors (imRECIST): Refining guidelines to assess the clinical benefit of cancer immunotherapy. J. Clin. Oncol. 2018, 36, 850–858. [CrossRef]

76. Sachpekidis, C.; Larribere, L.; Pan, L.; Haberkorn, U.; Dimitrakopoulou-Strauss, A.; Hassel, J.C. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: Preliminary results of an ongoing study. Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 386–396. [CrossRef]

77. Tan, A.C.; Emmett, L.; Lo, S.; Liu, V.; Kapoor, R.; Carlino, M.S.; Guminski, A.D.; Long, G.V.; Menzies, A.M. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Ann. Oncol. 2018, 29, 2115–2120. [CrossRef]

78. Kaira, K.; Higuchi, T.; Naruse, I.; Arisaka, Y.; Tokue, A.; Altan, B.; Suda, S.; Mogi, A.; Shimizu, K.; Sunaga, N.; et al. Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 56–66. [CrossRef]

79. Pai, C.S.; Huang, J.T.; Lu, X.; Simons, D.M.; Park, C.; Chang, A.; Tamaki, W.; Liu, E.; Roybal, K.T.; Seagal, J.; et al. Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity 2019, 50, 477–492. [CrossRef]

80. Bellevue, D.; Petyt, G.; Collet, G.; Hossein-foucher, C. [18F]-FDG-PET/CT early response to nivolumab in NSCLC. J. Nucl. Med. 2019, 57, 135. [CrossRef]

81. Grizzi, F.; Castello, A.; Lopci, E. Is it time to change our vision of tumor metabolism prior to immunotherapy? Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 1072–1075. [CrossRef] [PubMed]

82. Fuser, D.; Hernandez-Aya, L.; Mhlanga, J.; Crandall, J.; Ash, L.; Wahl, R.; Chen, D. Evaluation of 18F-FDG-PET/CT for Response Assessment in Patients with Advanced Melanoma Treated with Pembrolizumab Checkpoint Inhibitor Monotherapy. J. Nucl. Med. 2018, 59, 133.

83. Evangelista, L.; Cuppari, L.; Menis, J.; Bonanno, L.; Reccia, P.; Frega, S.; Pasello, G. 18F-FDG-PET/CT in non-small-cell lung cancer patients. Nucl. Med. Commun. 2019, 40, 802–807. [CrossRef] [PubMed]

84. Chang, B.; Huang, A.; Shang, C.; Palmer, K.; Schubert, E.; Xu, W.; Amaravadi, R.; Schuchter, L.; Mitchell, T.; Wherry, E.; et al. Evaluation of the anti-PD-1 flare response in patients with advanced melanoma using FDG PET/CT imaging and hematologic biomarkers. J. Nucl. Med. 2019, 60, 2019–2020.

85. Cho, S.Y.; Lipson, E.J.; Im, H.J.; Rowe, S.P.; Gonzalez, E.M.; Blackford, A.; Chirindel, A.; Pardoll, D.M.; Topalian, S.L.; Wahl, R.L. Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET/CT imaging in patients with advanced melanoma. J. Nucl. Med. 2017, 58, 1421–1428. [CrossRef] [PubMed]

86. Anwar, H.; Sachpekidis, C.; Winkler, J.; Kopp-Schneider, A.; Haberkorn, U.; Hassel, J.C.; Dimitrakopoulou-Strauss, A. Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 376–383. [CrossRef]

87. Sachpekidis, C.; Anwar, H.; Winkler, J.; Kopp-Schneider, A.; Larribere, L.; Haberkorn, U.; Hassel, J.C.; Dimitrakopoulou-Strauss, A. The role of interim 18 F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 1289–1296. [CrossRef]

88. Goldfarb, L.; Duchemann, B.; Chouahnia, K.; Zelek, L.; Soussan, M. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: Introduction of iPERCIST. EJNMMI Res. 2019, 9, 1–10. [CrossRef]

89. Aide, N.; Hicks, R.J.; Le Tourneau, C.; Lheureux, S.; Fanti, S.; Lopci, E. FDG PET/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 238–250. [CrossRef]
90. Garon, E.B.; Hellmann, M.D.; Rizvi, N.A.; Carcereny, E.; Leighl, N.B.; Ahn, M.J.; Eder, J.P.; Balmanoukian, A.S.; Aggarwal, C.; Horn, L.; et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: Results from the phase I KEYNOTE-001 study. *J. Clin. Oncol.* 2019, 37, 2518–2527. [CrossRef]

91. Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Rutkowski, P.; Lao, C.D.; Cowey, C.L.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *N. Engl. J. Med.* 2019, 381, 1535–1546. [CrossRef] [PubMed]

92. Otoshi, T.; Nagano, T.; Tachihara, M.; Nishimura, Y. Possible biomarkers for cancer immunotherapy. *Cancers* 2019, 11, 935. [CrossRef] [PubMed]

93. Hwang, S.; Kwon, A.Y.; Jeong, J.Y.; Kim, S.; Kang, H.; Park, J.; Kim, J.H.; Han, O.J.; Lim, S.M.; An, H.J. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. *Sci. Rep.* 2020, 10, 1–10. [CrossRef] [PubMed]

94. Davis, A.A.; Patel, V.G. The role of PD-L1 expression as a predictive biomarker: An analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors. *J. Immunother. Cancer* 2019, 7, 278. [CrossRef]

95. Smit, E.F.; de Langen, A.J. Pembrolizumab for all PD-L1-positive NSCLC. *Lancet* 2019, 393, 1776–1778. [CrossRef]

96. Munari, E.; Zamboni, G.; Lunardi, G.; Marchionni, L.; Marconi, M.; Sommaglio, M.; Brunelli, M.; Martignoni, G.; Netto, G.J.; Hoque, M.O.; et al. PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. *J. Thorac. Oncol.* 2018, 13, 1113–1120. [CrossRef]

97. Chen, D.S.; Mellman, I. Oncology meets immunology: The cancer-immunity cycle. *Immunity* 2013, 39, 1–10. [CrossRef]

98. Yonesaka, K.; Haratani, K.; Takamura, S.; Sakai, H.; Kato, R.; Takegawa, N.; Takahama, T.; Tanaka, K.; Hayashi, H.; Takeda, M.; et al. B7-h3 negatively modulates ctl-mediated cancer immunity. *Clin. Cancer Res.* 2018, 24, 2653–2664. [CrossRef]

99. Nebhan, C.A.; Johnson, D.B. Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. *Expert Rev. Anticancer Ther.* 2020, 8049, 2019–2020. [CrossRef]

100. Petitprez, F.; Sun, C.-M.; Lacroix, L.; Sautès-Fridman, C.; de Reyniès, A.; Fridman, W.H. Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. *Front. Oncol.* 2018, 8, 390. [CrossRef]

101. Tavare, R.; Escuin-Ordinas, H.; Mok, S.; McCracken, M.N.; Zettlitz, K.A.; Salazar, F.B.; Witte, O.N.; Ribas, A.; Wu, A.M. An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. *Cancer Res.* 2016, 76, 73–82. [CrossRef] [PubMed]

102. Rashidian, M.; Ingram, J.R.; Dougan, M.; Dongre, A.; Whang, K.A.; LeGall, C.; Cragnolini, J.J.; Bierie, B.; Gostissa, M.; Gorman, J.; et al. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. *J. Exp. Med.* 2017, 214, 2243–2255. [CrossRef] [PubMed]

103. Loose, D.; Signore, A.; Staelens, L.; Vandenbergulcke, K.; Vermeersch, H.; Dierckx, R.A.; Bonanno, E.; Van De Wiele, C. 123I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma. *Eur. J. Nucl. Med. Mol. Imaging* 2008, 35, 281–286. [CrossRef]

104. Renard, V.; Staelens, L.; Signore, A.; Van Belle, S.; Dierckx, R.A.; Van De Wiele, C. Iodine-123-interleukin-2 scintigraphy in metastatic hypernephroma: A pilot study. *Q. J. Nucl. Med. Mol. Imaging* 2007, 51, 352–356. [PubMed]

105. Signore, A.; Lauri, C.; Auletta, S.; Anzola, K.; Galli, F.; Casali, M.; Versari, A.; Glaudemans, A.W.J.M. Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology. *J. Clin. Med.* 2019, 8, 681. [CrossRef] [PubMed]

106. Markovic, S.N.; Galli, F.; Suman, V.J.; Nevala, W.K.; Paulsen, A.M.; Hung, J.C.; Gansen, D.N.; Erickson, L.A.; Marchetti, P.; Wiseman, G.A.; et al. Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: A pilot study. *Oncotarget* 2018, 9, 30268–30278. [CrossRef]
107. Beckford Vera, D.R.; Smith, C.C.; Bixby, L.M.; Glatt, D.M.; Dunn, S.S.; Saito, R.; Kim, W.Y.; Serody, J.S.; Vincent, B.G.; Parrott, M.C. Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. *PLoS ONE* 2018, 13, e0193832. [CrossRef]

108. Higashikawa, K.; Yagi, K.; Watanabe, K.; Kamino, S.; Ueda, M.; Hiromura, M.; Enomoto, S. 64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. *PLoS ONE* 2014, 9, e0193832. [CrossRef]

109. Ehlerding, E.B.; England, C.G.; Majewski, R.L.; Valdovinos, H.F.; Jiang, D.; Liu, G.; McNeel, D.G.; Nickles, R.J.; Cai, W. ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer. *Mol. Pharm.* 2017, 14, 1782–1789. [CrossRef]

110. England, C.G.; Jiang, D.; Ehlerding, E.B.; Rekoske, B.T.; Ellison, P.A.; Hernandez, R.; Barnhart, T.E.; McNeel, D.G.; Huang, P.; Cai, W. 89 Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. *Eur. J. Nucl. Med. Mol. Imaging* 2018, 45, 110–120. [CrossRef]

111. Natarajan, A.; Mayer, A.T.; Reeves, R.E.; Gano, J.; Gambhir, S.S. Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. *Bioconjug. Chem.* 2015, 26, 2062–2069. [CrossRef] [PubMed]

112. Natarajan, A.; Patel, C.B.; Habte, F.; Gambhir, S.S. Dosimetry Prediction for Clinical Translation of 64Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression. *Sci. Rep.* 2018, 8, 633. [CrossRef] [PubMed]

113. Natarajan, A.; Mayer, A.T.; Reeves, R.E.; Nagamine, C.M.; Gambhir, S.S. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. *Mol. Imaging Biol.* 2017, 19, 903–914. [CrossRef]

114. Kelly, M.P.; Tavare, R.; Giurleo, J.T.; Makonnen, S.; Hickey, C.; Danton, M.A.; Arnold, T.C.; Ma, D.; Dai, J.; Pei, J.; et al. Abstract 3033: Immuno-PET detection of LAG-3 expressing intratumoral lymphocytes using the zirconium-89 radiolabeled fully human anti-LAG-3 antibody REGN3767. In Proceedings of the Cancer Research; American Association for Cancer Research (AACR): Philadelphia, PA, USA, 2018; Volume 78, p. 3033.

115. Jagoda, E.M.; Vasalatiy, O.; Basuli, F.; Opina, A.C.L.; Williams, M.R.; Wong, K.; Lane, K.C.; Adler, S.; Ton, A.T.; Szajek, L.P.; et al. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. *Mol. Imaging* 2019, 18. [CrossRef]

116. Lv, G.; Sun, X.; Qiu, L.; Sun, Y.; Li, K.; Liu, Q.; Zhao, Q.; Qin, S.; Lin, J. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody. *J. Nucl. Med.* 2020, 61, 117–122. [CrossRef] [PubMed]

117. Burvenich, I.J.G.; Parakh, S.; Lee, F.T.; Guo, N.; Liu, Z.; Gan, H.K.; Rigopoulos, A.; O’Keefe, G.J.; Gong, S.J.; Goh, Y.W.; et al. Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a. *Theranostics* 2018, 8, 4199–4209. [CrossRef] [PubMed]

118. Ulaner, G.; Sobol, N.; O’Donoghue, J.; Burnazi, E.; Staton, K.; Weber, W.; Lyashchenko, S.; Lewis, J.; Landgren, C.O. Preclinical development and First-in-human imaging of 89Zr-Daratumumab for CD38 targeted imaging of myeloma. *J. Nucl. Med.* 2019, 60, 203. [CrossRef] [PubMed]

119. Toms, J.; Kogler, J.; Maschauer, S.; Daniel, C.; Schmidkonz, C.; Kuwert, T.; Prante, O. Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-labeled FAP Inhibitor. *J. Nucl. Med.* 2020. [CrossRef]

120. Loktev, A.; Lindner, T.; Mier, W.; Debus, J.; Altmann, A.; Jäger, D.; Giesel, F.; Kratochwil, C.; Barthel, P.; Roumestand, C.; et al. A tumor-imaging method targeting cancer-associated fibroblasts. *J. Nucl. Med.* 2018, 59, 1423–1429. [CrossRef]

121. Prasetyanti, P.R.; Medema, J.P. Intra-tumor heterogeneity from a cancer stem cell perspective. *Mol. Cancer* 2017, 16, 41. [CrossRef]

122. Bu, L.; Baba, H.; Yoshida, N.; Miyake, K.; Yasuda, T.; Uchihara, T.; Tan, P.; Ishimoto, T. Biological heterogeneity and versatility of cancer- associated fibroblasts in the tumor. *Oncogene* 2018, 38, 4887–4901. [CrossRef]

123. Bailly, C.; Bodet-Milin, C.; Bourgeois, M.; Gouard, S.; Ansquer, C.; Barbaut, M.; Sébille, J.C.; Chérel, M.; Kraeber-Bodéré, F.; Carlier, T. Exploring tumor heterogeneity using PET imaging: The big picture. *Cancers* 2019, 11, 1282. [CrossRef] [PubMed]
124. Bensch, F.; van der Veen, E.; Lub-de Hooge, M.; Jorritsma-Smit, A. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1. *Nat. Med.* 2018, 24, 1852–1858. [CrossRef] [PubMed]

125. Niemeijer, A.N.; Leung, D.; Huisman, M.C.; Bahce, I.; Hoekstra, O.S.; van Dongen, G.A.M.S.; Boellaard, R.; Du, S.; Hayes, W.; Smith, R.; et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. *Nat. Commun.* 2018, 9, 4664. [CrossRef] [PubMed]

126. Xing, Y.; Chand, G.; Liu, C.; Cook, G.J.R.; O’Doherty, J.; Zhao, L.; Wong, N.C.L.; Meszaros, L.K.; Ting, H.H.; Zhao, J. Early phase I study of a 99mTe-labeled anti-programmed death ligand-1 (PD-L1) single-domain antibody in SPECT/CT assessment of PD-L1 expression in non-small cell lung cancer. *J. Nucl. Med.* 2019, 60, 1213–1220. [CrossRef]

127. Wang, Y.; Zhou, S.; Yang, F.; Qi, X.; Wang, X.; Guan, X.; Shen, C.; Duma, N.; Vera Aguilera, J.; Chintakuntlawar, A.; et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. *JAMA Oncol.* 2019, 5, 1008–1019. [CrossRef]

128. Haanen, J.B.A.G.; Carbonnel, F.; Robert, C.; Kerr, K.M.; Peters, S.; Larkin, J.; Jordan, K. ESMO Guidelines Committee Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.* 2017, 28, iv119–iv142. [CrossRef]

129. Brahmer, J.R.; Lacchetti, C.; Schneider, B.J.; Atkins, M.B.; Brassil, K.J.; Caterino, J.M.; Chau, I.; Ernstoff, M.S.; Gardner, J.M.; Ginex, P.; et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. *J. Clin. Oncol.* 2018, 36, 1714–1768. [CrossRef]

130. Martins, F.; Sotiya, L.; Syktios, G.P.; Lamine, F.; Maillard, M.; Fraga, M.; Shabafrouz, K.; Ribi, C.; Cairoli, A.; Guex-Crosier, Y.; et al. Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. *Nat. Rev. Clin. Oncol.* 2019, 16, 563–580. [CrossRef]

131. Mekki, A.; Dercole, L.; Lichtenstein, P.; Marabelle, A.; Michot, J.M.; Lambotte, O.; Le Pavec, J.; De Martin, E.; Balleyguier, C.; Champiat, S.; et al. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. *Eur. J. Cancer* 2018, 96, 91–104. [CrossRef]

132. Nishino, M.; Sholl, L.M.; Hatabu, H.; Armand, P.; Hodi, F.S. Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event. *Cancer Immunol. Res.* 2018, 6, 630–635. [CrossRef] [PubMed]

133. Van Willigen, W.W.; Gerritsen, W.R.; Aarntzen, E.H.J.G. 18F-FDG PET/CT of Multiorgan Sarcoid-Like Reaction during Anti-PD-1 Treatment for Melanoma. *Clin. Nucl. Med.* 2019, 44, 905–906. [CrossRef] [PubMed]

134. Lyall, A.; Vargas, H.A.; Carvajal, R.D.; Ulancer, G. Ipilimumab-induced colitis on FDG PET/CT. *Clin. Nucl. Med.* 2012, 37, 629–630. [CrossRef]

135. Alabed, Y.Z.; Aghayev, A.; Sakellis, C.; Van den Abbeele, A.D. Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT. *Clin. Nucl. Med.* 2015, 40, e528–e529. [CrossRef] [PubMed]

136. Wachsmann, J.W.; Ganti, R.; Peng, F. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT. *Acad. Radiol.* 2017, 24, 111–115. [CrossRef] [PubMed]

137. Calugareanu, A.; Rompteaux, P.; Bohelay, G.; Goldfarb, L.; Barrau, V.; Cucherousset, N.; Heidelberger, V.; Nault, J.-C.; Ziol, M.; Caux, F.; et al. Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma. *Immunotherapy* 2019, 11, 1005–1013. [CrossRef] [PubMed]

138. Iravani, A.; Osman, M.; Hofman, M.; Weppler, A. Response assessment and immune-related adverse events as detected by FDG PET/CT in patients treated with combined CTLA-4 and PD-1 checkpoint inhibitors as first-line therapy in advanced melanoma. *J. Nucl. Med.* 2019, 60, 647.

139. Haratani, K.; Hayashi, H.; Chiba, Y.; Kudo, K.; Yonesaka, K.; Kato, R.; Kaneda, H.; Hasegawa, Y.; Tanaka, K.; Takeda, M.; et al. Association of immune-related adverse events with nivolumab efficacy in non-small cell lung cancer. *JAMA Oncol.* 2018, 4, 374–378. [CrossRef]

140. Nobashi, T.; Baratto, L.; Reddy, S.A.; Srinivas, S.; Torihara, A.; Hatami, N.; Yohannan, T.K.; Mittra, E. Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT. *Clin. Nucl. Med.* 2019, 44, e272–e279. [CrossRef]

141. Yamauchi, I.; Yasoda, A.; Matsumoto, S.; Sakamori, Y.; Kim, Y.H.; Nomura, M.; Otsuka, A.; Yamasaki, T.; Saito, R.; Kitamura, M.; et al. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. *PLoS ONE* 2019, 14, e0216954. [CrossRef]
142. Lang, N.; Dick, J.; Slynko, A.; Schulz, C.; Dimitrakopoulou-Strauss, A.; Sachpekidis, C.; Enk, A.H.; Hassel, J.C. Clinical significance of signs of autoimmune colitis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. *Immunotherapy* 2019, 11, 667–676. [CrossRef] [PubMed]

143. Sachpekidis, C.; Larribère, L.; Kopp-Schneider, A.; Hassel, J.C.; Dimitrakopoulou-Strauss, A. Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma? *Cancer Immunol. Immunother.* 2019, 68, 297–303. [CrossRef] [PubMed]

144. Bianconi, F.; Palumbo, I.; Spanu, A.; Nuvoli, S.; Fravolini, M.L.; Palumbo, B. PET/CT Radiomics in Lung Cancer: An Overview. *Appl. Sci.* 2020, 10, 1718. [CrossRef]

145. Chen, R.Y.; Lin, Y.C.; Shen, W.C.; Hsieh, T.C.; Yen, K.Y.; Chen, S.W.; Kao, C.H. Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in 18F-FDG PET in Squamous Cell Carcinoma of the Head and Neck. *Sci. Rep.* 2018, 8, 105. [CrossRef]

146. Kirienko, M.; Cozzi, L.; Antunovic, L.; Lozza, L.; Fogliata, A.; Voulaz, E.; Rossi, A.; Chiti, A.; Sollini, M. Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery. *Eur. J. Nucl. Med. Mol. Imaging* 2018, 45, 207–217. [CrossRef]

147. Mu, W.; Tunali, I. Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. *Eur. J. Nucl. Med. Mol. Imaging* 2020, 47, 1168–1182. [CrossRef]

148. Nardone, V.; Tini, P.; Pastina, P.; Botta, C.; Reginelli, A.; Carbone, S.F.; Giannicola, R.; Calabrese, G.; Tebala, C.; Guida, C.; et al. Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab. *Oncol. Lett.* 2020, 19, 1559–1566. [CrossRef]

149. Id, T.K.; Everitt, S.; La Fontaine, M.D.; Van De Kamer, J.B.; Macmanus, M.P.; Vogel, W.V.; Callahan, J.; Sonke, J. F-fluorodeoxyglucose positron emission tomography radiomics features in non-small cell lung cancer: Are there any? *PLoS ONE* 2020, 15, e0228793.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).